The rise in infectious disease outbreaks globally is being driven by several factors, including increased global travel and urbanisation.

Merck KGaA has dosed the first patient in its Phase III PROCEADE-CRC-03 trial, assessing the investigational anti-CEACAM5 ADC precemtabart tocentecan for mCRC.

An upcoming conference will investigate the latest trends in the medical devices and medtech clinical trials industry with a focus on navigating recent regulatory changes. The Out ...

Lilly's retatrutide may have the best weight loss efficacy so far, but analysts are concerned around its tolerability compared with tirzepatide.

Biogen and Denali Therapeutics have reported data from the Phase IIb LUMA study evaluating BIIB122 for early-stage Parkinson’s disease.

Pfizer has reported positive results from its Phase II trial evaluating the 25-valent pneumococcal conjugate vaccine candidate, PF-07872412, in infants.

BioMarin Pharmaceutical has reported that its pivotal Phase III ENERGY 3 trial assessing BMN 401 in children aged one to 12 years with ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) ...

Today, 20 May, marks Clinical Trials Day. Editor Abigail Beaney spoke with CML patient Mel Mann who was one of the first patients to receive Gleevac.

As China continues to inch ahead of competition in terms of trial initiations, immunology and metabolic disease trials attract sponsor eyes.

As the first half of 2026 draws to a close, experts at Arena International’s OCT East Coast reflect on the key trends shaping the sector.

Itepekimab saddled with unclear clinical results for COPD in former smokers at ATS 2026. Credit: Jo Panuwat D/Shutterstock.com On 16 May, during the 2026 American Thoracic Society (ATS) International ...